高用量対標準用量インフルエンザワクチンと高齢者の心血管疾患のアウトカム: DANFLU-2 ランダム化臨床試験の予め指定された二次分析
Niklas Dyrby Johansen1,2, Daniel Modin1,2, Matthew M Loiacono3,4
1Department of Cardiology, Copenhagen University Hospital - Herlev and Gentofte, Copenhagen, Denmark.
JAMA cardiology
|August 30, 2025
まとめ
高用量不活性型インフルエンザワクチン (HD- IIV) は,標準用量IIV (SD- IIV) に比べて,高齢者の心臓呼吸器科入院を減少させた. これには心血管疾患と心不全による入院が少なくなったが,結果は探索的だ.
科学分野:
- 心臓病科
- 免疫学
- 公衆衛生
背景:
- 高用量非活性型インフルエンザワクチン (HD-IIV) は,標準用量IIV (SD-IIV) に比べて,インフルエンザ感染に対する優れた保護を提供します.
- HD-IIVの心臓血管 (CV) 効果に関する既存のデータは,主に観察研究または高リスク集団からのものです.
研究 の 目的:
- デンマークの高齢者集団における心血管疾患に対するHD-IIVとSD-IIVの相対的なワクチン有効性 (rVE) を決定する.
- 大規模なランダム化臨床試験において,事前に指定された二次エンドポイントとしてCVアウトカムを分析する.
主な方法:
- 33万人以上の高齢者 (≥65歳) を対象とした実用的でオープンな個別ランダム化臨床試験 (DANFLU-2).
- 参加者はランダムに1対1でHD-IIVまたはSD-IIVを投与された.
- ワクチン接種後14日から翌年の5月31日までの重篤なCVアウトカムを追跡するために,全国的な行政衛生登録を使用した.
主要な成果:
- HD- IIVはプライマリエンドポイント (インフルエンザ/肺炎入院) を有意に減少させなかった.
- どんな心肺疾患でも入院率はHD- IIVでは低かった (rVE,5. 7%).
- どんな心血管疾患 (rVE,7. 5%) や心不全 (rVE, 19. 5%) に関する入院もHD- IIVで減少した.
結論:
- HD- IIVは,SD- IIVと比較して,高齢者の心臓呼吸器科入院の発生率を低下させた.
- 観察された利点は,心筋梗塞,特に心不全の入院率の低下によるものです.
- これらの発見は,試験の中立な原始的結果を考慮して,探索的なものとみなされます.
関連する概念動画
Coronary Artery Disease IV: Preventive Measures
32
Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
32
Vaccinations
45.3K
Overview
45.3K
Cardiovascular Drugs: Classification based on Therapeutic Indications
3.2K
Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However,...
3.2K
Heart Failure III: Clinical Manifestations
42
Heart failure (HF) manifests primarily as dyspnea, fatigue, and fluid retention, resulting in peripheral and pulmonary edema. Symptoms may vary depending on which ventricle is more affected, left or right.Left-Sided Heart FailureAlso known as left ventricular failure, this condition results from the left ventricle's inability to fill or eject sufficient blood into the systemic circulation. It leads to pulmonary congestion, which occurs when the left ventricle fails to eject blood effectively...
42
Insulin: Dosing Regimen and Adverse Effects
253
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
253
Heart Failure V: Medical Management
23
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
23


